Abstract
Background: According to the textbooks, the ketotic glycogen storage disease (GSD) types 0, III, VI, IX, and XI are associated with fasting ketotic hypoglycemia and considered milder as gluconeogenesis is intact.
Methods: A retrospective cohort study of biochemical profiles from supervised clinical fasting studies is performed in ketotic GSD patients in our metabolic center. For data analysis, hypoglycemia was defined as plasma glucose concentration <2.6 mmol/L. Total KB was defined as the sum of blood acetoacetate and β-hydroxybutyrate concentrations. If the product of glucose and KB concentrations was greater than 10, a ketolysis defect was suspected.
Results: Data could be collected from 13 fasting studies in 12 patients with GSD III (n = 4), GSD VI (n = 3), and GSD IX (n = 5). Six patients remained normoglycemic with median glucose concentration of 3.9 mmol/L (range, 2.8–4.6 mmol/L) and median total KB concentration of 1.9 mmol/L (range, 0.6–5.1 mmol/L). The normoglycemic patients included type VI (3 out of 3) and type IX (3 out of 5) patients. All type III patients developed ketotic hypoglycemia. Interestingly, in five patients (one GSD III, one GSD VI, and three GSD IX), the biochemical profile suggested a ketolysis defect.
Conclusion: Normoglycemic ketonemia is a common biochemical presentation in patients with GSD types VI and IX, and ketonemia can precede hypoglycemia in all studied GSD types. Therefore, GSD VI and GSD IX should be added to the differential diagnosis of ketotic normoglycemia, and KB concentrations should be routinely measured in ketotic GSD patients.
Keywords
- Plasma Glucose Concentration
- Glycogen Storage Disease
- Glycogen Storage Disease Type
- Dietary Management
- Mitochondrial Fatty Acid Oxidation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Competing interests: None declared
This is a preview of subscription content, access via your institution.
Buying options
Abbreviations
- FI:
-
Fasting intolerance
- GSD:
-
Glycogen storage disease
- KBs:
-
Ketone bodies
References
Bali D, Goldstein J, Fredrickson K, Rehder C, Boney A, Austin S (2014) Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene. Mol Genet Metab 111:309–313
Beauchamp NJ, Taybert J, Champion MP, Layet V, Heinz-Erian P, Dalton A et al (2007a) High frequency of missense mutations in glycogen storage disease type VI. J Inherit Metab Dis 30:722–734
Beauchamp NJ, Dalton A, Ramaswami U, Niinikoski H, Mention K, Kenny P et al (2007b) Glycogen storage disease type IX: high variability in clinical phenotype. Mol Genet Metab 92:88–99
Bonnefont JP, Specola NB, Vassault A, Lombes A, Ogier H, de Klerk JBC et al (1990) The fasting test in paediatrics: application to the diagnosis of pathological hypo- and hyperketotic states. Eur J Pediatr 150:80–85
Brown LM, Corrado MM, van der Ende RM, Derks TGJ, Chen M, Siegel S et al (2014) Evaluation of glycogen storage disease as a cause of ketotic hypoglycemia in children. J Inherit Metab Dis 38:489–493
Clemente M, Gussinyer M, Arranz JA, Riudor E, Yeste D, Albisa M, Carrascosa A (2010) Glycogen storage disease type III with hypoketosis. J Pediatr Endocrinol Metab 23:833–836
Cornblath M, Hawdon JM, Williams AF, Aynsley-Green A, Ward-Platt MP, Schwartz R et al (2000) Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. Pediatrics 105:1141–1145
D’Orazio P, Burnett R, Fogh-Andersen N, Jacobs E, Kuwa K, Kulpman W et al (2005) Approved IFCC recommendation on reporting results for blood glucose. Clin Chem 51:1573–1576
Dagli A, Weinstein D (2009) Glycogen storage disease type VI. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews. University of Washington, Seattle
Dagli A, Sentner C, Weinstein D (2010) Glycogen storage disease type III. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews. University of Washington, Seattle
Derks TGJ, Smit GPA (2015) Dietary management in glycogen storage disease type III: what is the evidence ? J Inherit Metab Dis 38:545–550
Derks TGJ, van Rijn M (2015) Lipids in hepatic glycogen storage diseases: pathophysiology monitoring of dietary management and future directions. J Inherit Metab Dis 38:537–543
Goldstein J, Austin S, Kishnani P et al (2011) Phosphorylase kinase deficiency. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews. University of Washington, Seattle
Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, Case LE et al (2010) Glycogen storage disease type III diagnosis and management guidelines. Genet Med 12:446–463
Koh TH, Aynsley-Green A, Tarbit M, Eyre J (1988) Neural dysfunction during hypoglycaemia. Arch Dis Child 63:1353–1358
Laforêt P, Weinstein DA, Smit GPA (2012) The glycogen storage diseases and related disorders. In: Saudubray JM, van de Berghe G, Walter J (eds) Inborn metabolic diseases: diagnosis and treatment. Springer, Berlin
Millington DS, Kodo N, Norwood DL, Roe CR (1990) Tandem mass-spectrometry - a new method for acylcarnitine profiling with potential for neonatal screening for inborn-errors of metabolism. J Inherit Metab Dis 13:321–324
Seigel J, Weinstein DA, Hillman R, Colbert B, Matthews B, Bachrab B (2008) Glycogen storage disease type IIIa presenting as non-ketotic hypoglycemia: use of a newly approved commercially available mutation analysis to non-invasively confirm the diagnosis. J Pediatr Endocrinol Metab 6:587–590
Touati G, Mochel F, Rabier D (2012) Diagnostic procedures: functional tests and post-mortem protocol. In: Saudubray JM, van den Berghe G, Walter J (eds) Inborn metabolic diseases: diagnosis and treatment. Springer, Berlin
Van Veen MR, van Hasselt PM, de Sain-van der Velden MGM, Verhoeven N, Hofstede FC, de Koning TJ et al (2011) Metabolic profiles in children during fasting. Pediatrics 127:1021–1027
Wang J, Cui H, Lee N-C, Hwu W-L, Chien Y-H, Craigen WJ et al (2012) Clinical application of massively parallel sequencing in the molecular diagnosis of glycogen storage diseases of genetically heterogeneous origin. Genet Med 15:106–114
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Verena Peters
Compliance with Ethics Guidelines
Compliance with Ethics Guidelines
Conflict of Interest
Francjan J. van Spronsen has received research grants and consultancy and speaker’s fees from Merck Serono and Danone Nutricia. He is a member of the scientific advisory board of Merck Serono and chair of the scientific advisory board of Danone Nutricia. In the last 5 years, Terry G. J. Derks has received speaker’s fees from Danone Nutricia, Vitaflo, and Recordati and research fees from Sigma Tau and Vitaflo. Irene J. Hoogeveen, Rixt M. van der Ende, Foekje de Boer, and M. Rebecca Heiner-Fokkema declare that they have no conflict of interest to disclose.
Funding Source
No funding was secured for this study.
Financial Disclosure
The authors have no financial relationship relevant to this article.
Contributions of Individual Authors
Irene J. Hoogeveen and Rixt M. van der Ende collected and analyzed data from supervised clinical fasting studies, performed the data analysis, drafted the first version of the manuscript, and wrote the final manuscript.
Francjan J. van Spronsen was involved in clinical management and monitoring, critically reviewed and revised the manuscript, and approved the final manuscript as submitted.
Foekje de Boer was involved in dietary management, critically reviewed and revised the manuscript, and approved the final manuscript as submitted.
M. Rebecca Heiner-Fokkema supervised the data analysis of the fasting studies, critically reviewed and revised the manuscript, and approved the final manuscript as submitted.
Terry G. J. Derks initiated this study, was involved in clinical management and monitoring, drafted the first version of the manuscript, critically reviewed and revised the manuscript, and wrote the final manuscript.
All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. All authors confirm the absence of previous similar or simultaneous publications.
Informed Consent
All procedures followed were in accordance with the ethical standards of the institutional responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. Since all data were retrieved retrospectively and analyses anonymously, no informed consent was needed.
Rights and permissions
Copyright information
© 2015 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hoogeveen, I.J., van der Ende, R.M., van Spronsen, F.J., de Boer, F., Heiner-Fokkema, M.R., Derks, T.G.J. (2015). Normoglycemic Ketonemia as Biochemical Presentation in Ketotic Glycogen Storage Disease. In: Morava, E., Baumgartner, M., Patterson, M., Rahman, S., Zschocke, J., Peters, V. (eds) JIMD Reports, Volume 28. JIMD Reports, vol 28. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2015_511
Download citation
DOI: https://doi.org/10.1007/8904_2015_511
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-52846-4
Online ISBN: 978-3-662-52847-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)